United Kingdom· GB-APID-42176011000001100
Elfabrio 20mg/10ml concentrate for solution for infusion vials
A pegunigalsidase alfa product containing pegunigalsidase alfa, registered in United Kingdom by Chiesi Ltd. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Pegunigalsidase alfa is registered in 12 of 19 countries.
Countries holding a registration under ATC A16AB20 (pegunigalsidase alfa), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Pegunigalsidase alfa · ATC A16AB20
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Pegunigalsidase alfa
- Manufacturer
- Chiesi Ltd
- Country
- United Kingdom (GB)
- ATC code
- A16AB20
- ATC class
- Pegunigalsidase alfa
- Defined daily dose
- 5 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin05028613003381
- gtin5028613003381
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pegunigalsidase alfa in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaELFABRIOChiesi Farmaceutici S.p.A., Parma
- SwitzerlandElfabrio
- BelgiumElfabrio 2 mg/mlChiesi Farmaceutici
- FinlandElfabrioOrifarm Oy
- United StatesELFABRIOChiesi USA, Inc.
- IrelandElfabrio 2 mg/ml Concentrate for solution for infusionChiesi Farmaceutici S.p.A.
- IcelandElfabrioChiesi Farmaceutici S.p.A.*
- NetherlandsElfabrio 2 mg/ml concentraat voor oplossing voor infusieChiesi Farmaceutici S.p.A.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Elfabrio
- Liechtenstein · Elfabrio
- Norway · Elfabrio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/740798c8-2962-43fd-9772-d3419e635575 GET /v1/drugs/740798c8-2962-43fd-9772-d3419e635575?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42176011000001100",
"desc": "Elfabrio 20mg/10ml concentrate for solution for infusion vials (Chiesi Ltd)",
"form": "Solution for infusion",
"vpid": "42390411000001105",
"source": "dmd",
"vtm_id": "42389511000001102",
"strength": "2 mg",
"substance": "Pegunigalsidase alfa",
"ingredient": "Pegunigalsidase alfa",
"supplier_code": "9052511000001105"
}See everything about pegunigalsidase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.